RESOLVE: Relevance and Efficiency of SecOnd Line Workup for Uveitis

Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06102408
Collaborator
(none)
300
1.3

Study Details

Study Description

Brief Summary

The first-line etiological workup is currently poorly codified, and some patients undergo sequential investigations. However, the reason which lead the clinician to perform subsequent exams, and the relevance of such exams, remain to be determined. The main objective of the study was to assess the relevance of a second-line workup of patients with uveitis.

Condition or Disease Intervention/Treatment Phase
  • Other: second line investigations for uveitis etiological workup

Detailed Description

The first-line etiological workup is currently poorly codified, with some patients undergoing extensive investigations, and other minimal etiological workup. In addition, some patients undergo sequential investigations. However, the reason which lead the clinician to perform subsequent exams, and the relevance of investigations performed after a first line workup remain to be determined. The main objective of the study was to assess the relevance of a second-line workup of patients with uveitis.Secondary objectives were to describe the reasons of these second-line workups, and to determine which exams were the most relevant, and the determinants of its realization.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Relevance and Efficiency of SecOnd Line Workup for Uveitis
Anticipated Study Start Date :
Nov 15, 2023
Anticipated Primary Completion Date :
Dec 15, 2023
Anticipated Study Completion Date :
Dec 25, 2023

Arms and Interventions

Arm Intervention/Treatment
Patients with only one etiological workup

patients who underwent only one set of exams for etiological investigations of uveitis

Other: second line investigations for uveitis etiological workup
Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).

Patients without diagnostic modification subsequently to the second etiological workup

Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was not modified by the second line investigations.

Other: second line investigations for uveitis etiological workup
Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).

Patients with diagnostic modification subsequently to the second etiological workup

Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was modified by the second line investigations.

Other: second line investigations for uveitis etiological workup
Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).

Outcome Measures

Primary Outcome Measures

  1. patients undergoing a second line etiological workup [through study completion, an average of 18 months]

    percentage of patients undergoing a second line etiological workup

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • adult patient

  • at least one etiological workup in our center

Exclusion Criteria:
  • only episode of acute anterior uveitis quickly responding to topical treatments

  • diagnostic ophthalmologically obvious

  • opposition to collection of data

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Central Hospital, Nancy, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Thomas MOULINET, Principal Investigator, Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT06102408
Other Study ID Numbers:
  • 2023PI190
First Posted:
Oct 26, 2023
Last Update Posted:
Oct 27, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 27, 2023